Dr. Kasner

Margaret T. Kasner, MD

Contact Dr. Kasner

925 Chestnut Street
Suite 220A
Philadelphia, PA 19107

(215) 955-8874

Most Recent Peer-reviewed Publications

  1. Sirolimus enhances remission induction in patients with high risk acute myeloid leukemia and mTORC1 target inhibition
  2. Chronic myelomonocytic leukemia with central nervous system involvement
  3. Higher rates of relapse in maternal recipients of haploidentical hematopoietic stem cell transplantation from adult offspring donors for AML and myelodysplastic syndrome
  4. Acquired uniparental disomy in chromosome 6p as a feature of relapse after T-cell replete haploidentical hematopoietic stem cell transplantation using cyclophosphamide tolerization
  5. Disseminated Nocardia cyriacigeorgia causing pancreatitis in a haploidentical stem cell transplant recipient
  6. Acute myeloid leukemia patients’ clinical response to idasanutlin (RG7388) is associated with pre-treatment MDM2 protein expression in leukemic blasts
  7. A Two-Step Haploidentical Versus a Two-Step Matched Related Allogeneic Myeloablative Peripheral Blood Stem Cell Transplantation
  8. Polo-like kinase and its inhibitors: Ready for the match to start?
  9. A two-step approach to myeloablative haploidentical transplantation: Low nonrelapse mortality and high survival confirmed in patients with earlier stage disease
  10. Induced differentiation of acute myeloid leukemia cells by activation of retinoid X and liver X receptors
  11. Clostridium difficile colonization and disease in patients undergoing hematopoietic stem cell transplantation
  12. Treatment of adult ALL: More questions than answers
  13. Single-cell pharmacodynamic monitoring of S6 ribosomal protein phosphorylation in AML blasts during a clinical trial combining the mTOR inhibitor sirolimus and intensive chemotherapy
  14. A2-step approach to myeloablative haploidentical stem cell transplantation: A phase 1/2 trial performed with optimized T-cell dosing
  15. Novel targets for treatment of adult acute lymphocytic leukemia
  16. A phase I study of the mammalian target of rapamycin inhibitor sirolimus and MEC chemotherapy in relapsed and refractory acute myelogenous leukemia
  17. Update on the therapy for myelodysplastic syndrome
  18. Trisomy 8 in an allogeneic stem cell transplant recipient representative of a donor-derived constitutional abnormality
  19. Increased cerebral blood flow after leukapheresis for acute myelogenous leukemia